Skip to main content
. 2018 Aug 31;9(68):32958–32971. doi: 10.18632/oncotarget.26010

Figure 2. Prognosis analysis of MAP17 expression in rectal tumors after concurrent chemoradiotherapy.

Figure 2

(A, B) Association between MAP17 protein expression assessed by IHC to survival in the rectal tumor cohort. (A) Overall survival (OS) and (B) disease-free survival (DFS) Kaplan-Meier survival curves based on MAP17 protein expression. (C) mRNA MAP17 expression by risk group in TCGA rectal tumors cohort. (D) mRNA MAP17 expression by responders or non-responders in TCGA rectal tumors cohort. (E) Kaplan–Meier accumulated survival curve according to time to metastasis by MAP17 mRNA expression.